Vergoeding 2020-2024 voor ATC-subgroep L04AB : Tumornecrosefactor-alfa-antagonisten
- Raming voor de totale Zvw-populatie
| 2020 | 2021 | 2022 | 2023* | 2024* | |
|---|---|---|---|---|---|
| L04AB01 Etanercept | 41.215.022 | 33.043.474 | 23.148.319 | 21.905.211 | 21.161.487 |
| L04AB02 Infliximab | 70.410.390 | 63.349.357 | 52.468.927 | 49.533.546 | 45.975.804 |
| L04AB04 Adalimumab | 64.954.179 | 63.223.204 | 55.451.627 | 51.021.930 | 39.997.519 |
| L04AB05 Certolizumab pegol | 12.073.594 | 12.331.731 | 12.120.148 | 13.059.978 | 12.589.065 |
| L04AB06 Golimumab | 17.572.823 | 16.346.823 | 15.323.899 | 15.104.827 | 13.886.219 |
| Totaal | 206.226.008 | 188.294.590 | 158.512.919 | 150.625.492 | 133.610.094 |